<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737982</url>
  </required_header>
  <id_info>
    <org_study_id>RBSI14HNVT</org_study_id>
    <nct_id>NCT02737982</nct_id>
  </id_info>
  <brief_title>Sex and Gender Differences in Ischemic Heart Disease - Endocrine Vascular Disease Approach</brief_title>
  <acronym>EVA</acronym>
  <official_title>Sex and Gender Differences in Ischemic Heart Disease: From Bench to Bedside EVA (Endocrine Vascular Disease Approach)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Education, Universities and Research, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The application of sex-gender medicine is strongly recommended by World Health Organization&#xD;
      and other international organization. In fact, it is emerging that, although men and women&#xD;
      are affected to the same cardiovascular diseases (CVD), however they have different risk&#xD;
      factors, disease progression and response to pharmacological and not-pharmacological&#xD;
      treatments. Consequentially, the identification of biomarkers and therapeutic approaches&#xD;
      taking into account sex gender differences (SGD) is relevant to develop a really&#xD;
      evidence-based medicine.&#xD;
&#xD;
      With the aim of translate in clinical setting the more recently available basic research&#xD;
      evidences on estrogens and androgens balance involvement in modulation of&#xD;
      ischemia-reperfusion myocardial damage, the investigators planned to conduct a research study&#xD;
      on patients, affected by suspected or known ischemic heart disease (IHD) undergoing&#xD;
      angiography and/or percutaneous coronary interventions (PCI), aged more than 18 years of both&#xD;
      sex in ratio 1:1. Thus, in this setting, the goals of this proposal are:&#xD;
&#xD;
        1. To assess the sex-gender difference in entity of microvascular reperfusion damage in&#xD;
           patients with IHD undergoing urgent or elective PCI;&#xD;
&#xD;
        2. To evaluate estrogen/androgen-dependent and -independent effects in gender-related&#xD;
           differences on myocardial ischemia reperfusion damage occurring during PCI;&#xD;
&#xD;
        3. To investigate the differences in terms of platelet biology between men and women&#xD;
           affected by IHD undergoing urgent or elective PCI, matched for age and clinical&#xD;
           cardiovascular and metabolic characteristics;&#xD;
&#xD;
        4. To verify sex-driven interplay between response to PCI procedure, platelet function, sex&#xD;
           hormones and entity of reperfusion and myocardial damage, as well as, the impact on&#xD;
           clinical outcomes during a 1-year follow up.&#xD;
&#xD;
      This research study wants to explore and consequently elucidate biological mechanisms&#xD;
      responsible for sex-based differences in vivo human models of ischemia reperfusion myocardial&#xD;
      damage. Moreover, the investigators expected to clarify the impact of biological variables&#xD;
      evaluated on clinical outcomes after reperfusion therapeutic intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Assessment of corrected Thrombolysis In Myocardial Infarction frame count and myocardial blush grade</measure>
    <time_frame>baseline; within 1h from PCI</time_frame>
    <description>angiographic assessment of coronary flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual hormones levels in patients with IHD undergoing PCI</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluation and impact of sexual hormones levels in gender-related differences during myocardial reperfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet activation markers including Thromboxane, soluble cluster designation 40 (CD40) Ligand and soluble P-selectin in patients with IHD undergoing PCI</measure>
    <time_frame>baseline; within 1h from PCI; 12 months</time_frame>
    <description>Evaluation of Sex and gender differences in platelet function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes including cardiovascular mortality, re-hospitalization and restenosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular dysfunction assessed by cardiac magnetic resonance</measure>
    <time_frame>7 days from percutaneous coronary intervention</time_frame>
    <description>Among the EVA registry, we plan to perform a pilot study including: patients with stable angina with mono-vessel obstructive coronary artery disease (CAD) undergoing PCI; patients with stable angina undergoing angiography that documented no obstructive coronary disease (with a stenosis &lt;50%) with a impairment of microvascular dysfunction defined during angiography by a myocardial blush grade &lt;2 or coronary flow reserve &lt;2 after stress stimulus.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">509</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>IHD Men</arm_group_label>
    <description>Men with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IHD Women</arm_group_label>
    <description>Women with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>percutaneous coronary intervention</intervention_name>
    <description>coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion</description>
    <arm_group_label>IHD Men</arm_group_label>
    <arm_group_label>IHD Women</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women who referred with a suspected IHD to the cath-lab for undergoing percutaneous&#xD;
        coronary intervention&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with ischemic heart disease (acute or chronic) undergoing percutaneous&#xD;
             coronary intervention (urgent or elective)&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  both sex&#xD;
&#xD;
          -  aged more than 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with expectancy of life less than 12 months&#xD;
&#xD;
          -  active cancer&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valeria Raparelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Experimental Medicine Department, Sapienza University of Rome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico Umberto I , Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Valeria Raparelli</investigator_full_name>
    <investigator_title>University Reseacher</investigator_title>
  </responsible_party>
  <keyword>coronary heart disease</keyword>
  <keyword>gender</keyword>
  <keyword>platelet</keyword>
  <keyword>microvascular dysfunction</keyword>
  <keyword>sexual hormones</keyword>
  <keyword>cardiac magnetic resonance</keyword>
  <keyword>percutaneous coronary interventions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

